Payment overview · 2025
General Payments
$36,575.54
157 reported records · 14 companies
Healthcare provider profile · identity verified
Joseph Aragon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SANTA BARBARA, CA · NPI 1023122587
Verified facts
What the public records show
CMS Open Payments records show Joseph Aragon, M.D. received $36,575.54 in general payments during 2025 across 157 reported records.
Boston Scientific Corporation accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22,725.44 | 62.1% | 23 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $5,734.29 | 15.7% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $3,107.90 | 8.5% | 52 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $2,917.57 | 8.0% | 45 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$609.13 | 1.7% | 10 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $307.01 | 0.8% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $284.40 | 0.8% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $265.08 | 0.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.71 | 0.6% | 2 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $146.16 | 0.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.40 | 0.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $66.98 | 0.2% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $66.37 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.10 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,875.00 | 7 |
| Food and Beverage | $9,086.23 | 142 |
| Consulting Fee | $7,492.50 | 6 |
| Grant | $2,875.00 | 1 |
| Travel and Lodging | $246.81 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $11,555.94 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $6,134.46 | 8 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $4,209.29 | 9 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $2,875.00 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $1,849.19 | 40 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $1,562.50 | 1 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $1,525.00 | 2 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $945.87 | 17 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $816.59 | 17 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $640.69 | 9 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $358.32 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $307.01 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $284.40 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $284.40 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $284.40 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $284.40 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $284.40 | 2 | 2025 |
Source payment records
|
|||||
| NAEOTOM Alpha Normalized: naeotom alpha |
Device | Siemens Medical Solutions USA, Inc. | $265.08 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $245.36 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $235.38 | 2 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $224.06 | 4 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $204.09 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER Normalized: amplatzer |
Device | Abbott Laboratories | $199.60 | 3 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $182.23 | 1 | 2025 |
Source payment records
|
|||||
| NC TREK NEO Normalized: nc trek neo |
Device | Abbott Laboratories | $163.53 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $146.16 | 1 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $117.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.13 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $88.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.40 | 2 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $83.19 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $66.98 | 3 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $66.37 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $53.32 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $40.74 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $34.22 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| TYRX Normalized: tyrx |
Device | Medtronic, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $8.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
39 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 202 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 71 |
| Carvedilol | Carvedilol | 84 | 37 |
| Furosemide | Furosemide | 70 | 32 |
| Repatha Sureclick | Evolocumab | 67 | 14 |
| Lisinopril | Lisinopril | 62 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 22 |
| Eliquis | Apixaban | 55 | 21 |
| Losartan Potassium | Losartan Potassium | 54 | 27 |
| Entresto | Sacubitril/Valsartan | 47 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 19 |
| Ezetimibe | Ezetimibe | 41 | 18 |
| Xarelto | Rivaroxaban | 39 | 17 |
| Potassium Chloride | Potassium Chloride | 27 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,575.54 · 157 records | Boston Scientific Corporation | AFFERA MAPPING SYSTEM, AMPLATZER, AMPLATZER AMULET, AURORA EV-ICD MRI SURESCAN, AVVIGO Guidance System, Asahi Coronary Wires, COREVALVE EVOLUT R, DRAGONFLY OPSTAR, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVOQUE, FARAPULSE, FARXIGA, GORE CARDIOFORM Septal Occluder, General - EP, General - Structural Heart, General - Therapies, IGT Devices Systems Undivided, INVEGA SUSTENNA, LEQVIO, MICRA, MITRACLIP, NAEOTOM Alpha, NC TREK NEO, PRESSUREWIRE, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Product in Development, REPATHA, Rhythmia Mapping System, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TRICLIP, TYRX, VersaCross Access Solution, WATCHMAN, WATCHMAN Access System, XIENCE SKYPOINT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error